- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03235947
Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients (PERIFOS)
Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial)
A clinical controlled, randomized and double blind trial that included adult patients (≥18 years) receiving kidney transplantation (KT) at the INCMNSZ.
The intervention group will receive disodium fosfomycin 4 g intravenously in three moments: preoperative of transplant surgery, prior to removal of the urinary catheter and finally prior to removal of ureteral catheter. The control group will receive placebo in the same moments.
Both groups will receive prophylaxis standard for urinary tract infection (UTI), with trimethoprim/sulfamethoxazole 160/800 mg per day. This prophylaxis will be administered once the estimated glomerular filtration rate is greater than 30 mL/min/1.73m2.
The primary objective is to compare the average number of episodes of UTI´s and asymptomatic bacteriuria in both groups after 7 weeks of follow-up. The secondary objectives are to know the incidence of asymptomatic bacteriuria, the incidence of hospitalizations for IVU, the days of hospital stay, the pattern of bacterial resistance, the safety of disodium fosfomycin, and assessment of the function of the graft and rejection rate.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the context of development UTI in receptors of KT, some microbiological factors have raised great importance, mainly the antimicrobial drug resistance, which has been reported for TMP/SMX as high as 60 to 100%. Furthermore, it is also of increasing importance the recent isolation of multidrug-resistant bacteria, in particular ESBL-producing Escherichia coli and ampicillin-resistant Enterococcus. This phenomenon increases the rate of hospitalizations as well as the costs of hospital stay and antibiotic therapy. (1-3) In our institution, in receptors of KT the rate of TMP/SMX resistance is 89% and ESBL-production about 32% among E. coli recovered from urine. (4)
Because of the increase in the rate of TMP-SMX resistance, there is a lot of interest to use other antibiotics for the prevention of UTI among different populations. In this sense, fosfomycin is an agent with a unique mechanism of action that does not share with other families of known antibiotics, this characteristic provides advantages to use this antibiotic alone or, even, synergistically in combination with other antibiotics. Fosfomycin (FOS) is a wall antibiotic (pyruvyl-transferase inhibitor) that has shown a good bioavailability, especially in the urinary tract. It has shown a wide antibacterial spectrum, but the important target seems to be enteric bacilli particularly Escherichia coli (the most prevalent cause of UTI). FOS has also shown a very good activity against E. coli producer of Extended Spectrum Betalactamases.
Multiple clinical studies have shown FOS efficacy in the treatment of UTI's and especially in multiple-drug-resistant bacteria. (5) With regard to its use as a perioperative prophylaxis, in a systematic review with 8 trials, FOS proved to be effective to prevent health care-associated UTI's, however only one study showed no benefit. The oral dose regularly used is FOS 3 g, 3 hours before and 24 hours after the surgical procedure. (6)
Our hypothesis is that in the seven weeks after kidney transplantation, perioperative prophylaxis with FOS will show greater efficacy in comparison with standard prophylaxis (TMP/SMX). Considering that the mean number of UTI and BA episodes per patient in the first seven weeks is 0.8 episodes / patient, if we want to decrease it to 0.4 episodes per patient, using the means comparison formula will require 40 patients per arm per treatment, this considering a power of 80% and confidence intervals of 95%. The primary outcome will be to compare the mean number of episodes of urinary tract infection and asymptomatic bacteriuria per patient in each treatment arm. Secondary outcomes refer to the development of UTI-associated sepsis, pyelonephritis, recurrent UTI and asymptomatic bacteriuria. Safety outcomes included hematological and gastrointestinal side effects, the acute rejection rate, glomerular filtration rate, graft loss and patient death.
Patients eligible for a kidney transplant will be invited to participate in the study, prior to renal transplant surgery. They are given an informed consent, which is reviewed and approved by the ethics and research committees of our institution. The arms of the study are discussed in detail below. The study followed the Declaration of Helsinki recommendations and was approved by the Institutional Review Board (Ref: 1649). Randomization was conducted centrally by stratifying according to gender, with specific software (www.randomization.com). Patients were assigned to one of two parallel groups in a 1:1 ratio and in blocks of 4.
Subjects will be followed up for 7 weeks from renal transplant surgery. The outcome variables are defined as follows:
- Positive urine culture: The isolated germ will be defined depending on international standards. For enterobacteria and gram positive ≥100,000 colony-forming unit (CFU) / mL.
- Urinary tract infection: Positive urine culture plus presence of associated signs or symptoms.
- Significant Asymptomatic Bacteriuria: Will be identified from isolation ≥100,000 CFU/mL. In the case of women, the same insulation should be corroborated in a second urine culture sample.
- Asymptomatic Bacteriuria not significant: It will be identified from isolation of ≥1000 CFU/mL and will not be given antibiotic treatment.
- Hospitalization due to UTI: It will be defined as any UTI event that warrants hospitalization or that, having another reason for hospitalization, develop IVU that requires intravenous antimicrobial treatment.
The urine cultures will be taken from the first urine in the morning, obtaining the sample of medium jet with an approximate volume to collect of 25 to 50 mL. Urine samples were processed within the first hour after obtention.
The sample was inoculated in human blood agar and McConkey agar with a 1 microliter calibrated loop, and incubated at 35ºC, overnight. The report included the number of CFU. All clinical isolates were identified with the gram-negative and gram-positive identification cards by Vitek 2 (BioMérieux, Lyon, France) following the manufacturer´s instructions. AST-285 Vitek2 cards were used for gram-negative bacilli and the AST-591 Vitek2 card for gram-positive cocci (BioMérieux, Lyon, France); they were incubated and then interpreted by an expert in the system (version 7.01) and according to the Clinical & Laboratory Standards Institute (CLSI) M100-S24 (2014) guideline (20). Susceptibility to fosfomycin was determined by disk diffusion on cation-supplemented Müeller Hinton agar plates (CLSI, M07-A9); a bacterial suspension was inoculated in 0.5 mL Mc Farland, and a fosfomycin disk (200 micrograms [mcg]) supplemented with glucose-6-phosphate was used (50 mcg). Interpretation of inhibition halos in E. coli and Enterococcus faecalis isolates was based on CLSI M100-S24 (2014) criteria. The following were used as controls: E. coli ATCC 25922, E. coli ATCC 35218, Staphylococcus aureus ATCC 29213 and S. aureus ATCC 43300. Antimicrobial sensitivity to fosfomycin was determined with the microdilution broth method in E. coli, Klebsiella pneumoniae and Enterococcus spp. isolates. Müeller Hinton broth supplemented with glucose-6-phosphate (25 mcg/ml) was used, E. coli ATCC 25922, S. aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853 were included as controls and results were interpreted according to the CLSI (M07-A10) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2015 criteria (20,21).
Urine culture will be performed in the following situations: 1.- 48 hrs after the removal of the urinary catheter. 2.- Prior to removal of the ureteral catheter. 3.- At 4 weeks after renal transplantation. 4.- At 6 weeks after renal transplantation. 5.-In case of urinary storage symptoms suggestive of UTI or elevated creatinine (If the emergency department approach requires it). 6.- After antibiotic treatment of urinary tract infection or significant asymptomatic bacteriuria. In the case of women who have an episode of significant asymptomatic bacteriuria, this should be corroborated in two consecutive urine cultures.
Subjects will have the following follow-up visits: before ureteral catheter removal (first visit), 4 weeks of renal transplantation (second visit), 6 weeks (third visit) and one final visit at week 7.
Both follow-up visits and reports of urine cultures are recorded in the CRFs for each patient. In the follow-up consultations, adverse events will also be registered, if they are reported, are notified to the institutional committees and to the regulatory institutions of the health system of Mexico. An intermediate analysis will be carried out to determine both the effectiveness and safety of the interventions.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 14080
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients transplanted in the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.
Exclusion Criteria:
- Allergy to Fosfomycin disodium or Trimethoprim / Sulfamethoxazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fosfomycin disodium
|
Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
|
Active Comparator: Trimethoprim / Sulfamethoxazole
|
Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To compare the efficacy of Fosfomycin-disodium/Trimethoprim-sulfamethoxazole with Placebo/Trimetoprim-sulfamexazol in the prophylaxis of urinary tract infection or significant asymptomatic bacteriuria among kidney transplantation recipients.
Time Frame: 7-weeks after transplantation
|
The primary outcome in this clinical trial is the comparison of the mean number of episodes of urinary tract infection or significant asymptomatic bacteriuria, per patient in both arms of treatment among kidney transplantation recipients during the first seven weeks after surgery.
|
7-weeks after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The elapsed time period until the first urinary tract infection or asymptomatic bacteriuria developed
Time Frame: 7-weeks after transplantation
|
Refers to the elapsed time period until the first urinary tract infection or asymptomatic bacteriuria developed during the first 7 weeks post-KT
|
7-weeks after transplantation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of urinary tract infection
Time Frame: 7-weeks after transplantation
|
The number of patients that develope tract urinary infection in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
7-weeks after transplantation
|
Incidence of asymptomatic bacteriuria
Time Frame: 7-weeks after transplantation
|
The number of patients that develope asymptomatic bacteriuria in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
7-weeks after transplantation
|
Incidence of bacteremia
Time Frame: 7-weeks after transplantation
|
The number of patients that develope bacteremia in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
7-weeks after transplantation
|
Incidence of hospitalization for urinary tract infection
Time Frame: 7-weeks after transplantation
|
The number of patients that develope hospitalization for urinary tract infection in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
7-weeks after transplantation
|
Incidence of Clostridium difficile infection
Time Frame: 7-weeks after transplantation
|
The number of patients that develope Clostridium difficile infection in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
7-weeks after transplantation
|
Incidence of multidrug resistant bacteria colonization
Time Frame: 7-weeks after transplantation
|
The number of patients that develope multidrug resistant bacteria colonization infection in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
7-weeks after transplantation
|
Incidence of acute rejection
Time Frame: 3-months after transplantation
|
The number of patients that develope acute rejection in the first seven weeks after transplantation in each group, divided by the number of patients allocated in each group at randomization.
|
3-months after transplantation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jose Sifuentes-Osornio, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Publications and helpful links
General Publications
- Kawecki D, Kwiatkowski A, Sawicka-Grzelak A, Durlik M, Paczek L, Chmura A, Mlynarczyk G, Rowinski W, Luczak M. Urinary tract infections in the early posttransplant period after kidney transplantation: etiologic agents and their susceptibility. Transplant Proc. 2011 Oct;43(8):2991-3. doi: 10.1016/j.transproceed.2011.09.002.
- Linares L, Cervera C, Cofan F, Ricart MJ, Esforzado N, Torregrosa V, Oppenheimer F, Campistol JM, Marco F, Moreno A. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc. 2007 Sep;39(7):2222-4. doi: 10.1016/j.transproceed.2007.06.061.
- Senger SS, Arslan H, Azap OK, Timurkaynak F, Cagir U, Haberal M. Urinary tract infections in renal transplant recipients. Transplant Proc. 2007 May;39(4):1016-7. doi: 10.1016/j.transproceed.2007.02.060.
- Figueroa-Sánchez G, Arreola-Guerra JM, Morales-Buenrostro LE. Time of presentation and antimicrobial resistance pattern of urinary tract infection in the early period after kidney transplantation. Rev Mex Traspl 2016; 5: 20-26.
- Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009 Aug;34(2):111-20. doi: 10.1016/j.ijantimicag.2009.03.009. Epub 2009 Apr 28.
- Wagenlehner FM, Thomas PM, Naber KG. Fosfomycin trometamol (3,000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: a narrative review. Urol Int. 2014;92(2):125-30. doi: 10.1159/000355103. Epub 2013 Sep 13.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Document M100-S24. Wayne, PA: CLSI; 2014.
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. http://www.eucast.org
- Rosado-Canto R, Parra-Avila I, Tejeda-Maldonado J, Kauffman-Ortega C, Rodriguez-Covarrubias FT, Trujeque-Matos M, Cruz-Martinez R, Maravilla-Franco E, Criollo-Mora E, Arreola-Guerra JM, Morales-Buenrostro LE, Sifuentes-Osornio J. Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial. Nephrol Dial Transplant. 2020 Nov 1;35(11):1996-2003. doi: 10.1093/ndt/gfz261.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Disease Attributes
- Infections
- Communicable Diseases
- Urinary Tract Infections
- Bacteriuria
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Anti-Dyskinesia Agents
- Anti-Infective Agents, Urinary
- Renal Agents
- Cytochrome P-450 CYP2C8 Inhibitors
- Trimethoprim
- Sulfamethoxazole
- Fosfomycin
Other Study ID Numbers
- 1649
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection
-
Gloucestershire Hospitals NHS Foundation TrustUnknownCatheter Infection | Urinary Tract Infection in Pregnancy | Urinary Tract Infection Following Delivery
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
National Institute of Allergy and Infectious Diseases...TerminatedUrinary Tract InfectionUnited States
-
University Of PerugiaUnknownUrinary Tract Infection
-
NanovibronixShaare Zedek Medical CenterUnknownUrinary Tract InfectionIsrael
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)UnknownUrinary Tract InfectionCanada
-
Hadassah Medical OrganizationUnknown
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
Bactiguard ABRehab Station StockholmCompletedComplications; Catheter, Urinary Infection or InflammationSweden
Clinical Trials on Fosfomycin disodium
-
National Institute of Allergy and Infectious Diseases...CompletedPseudomonas InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedBacterial Infection | Pathogen Resistance | Multiple-drug ResistanceUnited States
-
Nabriva Therapeutics AGRecruitingPediatric ALLUnited States
-
Zealand University HospitalRegion Zealand; Costerton Biofilm Center; Reponex Pharmaceuticals A/SCompletedRight-sided Colon Cancer | Right-sided Colon AdenomaDenmark
-
Nabriva Therapeutics AGCompletedCardiac Repolarization in Healthy SubjectsUnited States
-
Drugs for Neglected DiseasesUniversity of Oxford; KEMRI-Wellcome Trust Collaborative Research ProgramCompletedNeonatal SEPSISKenya
-
Nabriva Therapeutics AGMedpace, Inc.CompletedAcute Pyelonephritis | Urinary Tract Infection Complicated | Urinary Tract Infection SymptomaticPoland, Ukraine, Belarus, Bulgaria, Romania, Greece, United States, Russian Federation, Hungary, Lithuania, Slovakia, Czechia, Latvia, Croatia, Georgia, Estonia
-
Bionorica SECompletedUrinary Tract InfectionGermany
-
Cardeas PharmaCompletedPneumonia, BacterialSpain, United States, Greece, Hungary, Turkey, Puerto Rico, France
-
Cardeas PharmaCompletedHealthyUnited States